314 related articles for article (PubMed ID: 28063190)
41. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
42. Frequent detection of
Chen Wongworawat Y; Eskandari G; Gaikwad A; Marcogliese AN; Ferguson LS; Brackett J; Punia JN; Elghetany MT; Kulkarni R; Rao PH; Ringrose J; Lopez-Terrada DH; Roy A; Curry CV; Fisher KE
Leuk Lymphoma; 2023 Feb; 64(2):462-467. PubMed ID: 36346368
[No Abstract] [Full Text] [Related]
43. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
[TBL] [Abstract][Full Text] [Related]
44. Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.
Inaba H; Zhou Y; Abla O; Adachi S; Auvrignon A; Beverloo HB; de Bont E; Chang TT; Creutzig U; Dworzak M; Elitzur S; Fynn A; Forestier E; Hasle H; Liang DC; Lee V; Locatelli F; Masetti R; De Moerloose B; Reinhardt D; Rodriguez L; Van Roy N; Shen S; Taga T; Tomizawa D; Yeoh AE; Zimmermann M; Raimondi SC
Blood; 2015 Sep; 126(13):1575-84. PubMed ID: 26215111
[TBL] [Abstract][Full Text] [Related]
45. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
46. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
47. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience.
Athale UH; Razzouk BI; Raimondi SC; Tong X; Behm FG; Head DR; Srivastava DK; Rubnitz JE; Bowman L; Pui CH; Ribeiro RC
Blood; 2001 Jun; 97(12):3727-32. PubMed ID: 11389009
[TBL] [Abstract][Full Text] [Related]
48.
Khanlari M; Wang L; Bolen CY; Otanez FSB; Furtado LV; Key L; Irwin L; Wang W; Klco JM
EJHaem; 2023 Aug; 4(3):765-769. PubMed ID: 37601875
[TBL] [Abstract][Full Text] [Related]
49. Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia.
Qi H; Mao Y; Cao Q; Sun X; Kuai W; Song J; Ma L; Hong Z; Hu J; Zhou G
Med Sci Monit; 2020 Jun; 26():e922662. PubMed ID: 32532951
[TBL] [Abstract][Full Text] [Related]
50. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
[TBL] [Abstract][Full Text] [Related]
51. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics.
Panda D; Chatterjee G; Sardana R; Khanka T; Ghogale S; Deshpande N; Badrinath Y; Shetty D; Narula G; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Mar; 100(2):206-217. PubMed ID: 32865882
[TBL] [Abstract][Full Text] [Related]
52. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome.
Lightfoot J; Hitzler JK; Zipursky A; Albert M; Macgregor PF
Leukemia; 2004 Oct; 18(10):1617-23. PubMed ID: 15343346
[TBL] [Abstract][Full Text] [Related]
53. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial.
Teyssier AC; Lapillonne H; Pasquet M; Ballerini P; Baruchel A; Ducassou S; Fenneteau O; Petit A; Cuccuini W; Ragu C; Preudhomme C; Mercher T; Sirvent N; Leverger G
Pediatr Hematol Oncol; 2017 Nov; 34(8):425-427. PubMed ID: 29303660
[TBL] [Abstract][Full Text] [Related]
54. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
55. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
56. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
[TBL] [Abstract][Full Text] [Related]
57. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.
Le Q; Hadland B; Smith JL; Leonti A; Huang BJ; Ries R; Hylkema TA; Castro S; Tang TT; McKay CN; Perkins L; Pardo L; Sarthy J; Beckman AK; Williams R; Idemmili R; Furlan S; Ishida T; Call L; Srivastava S; Loeb AM; Milano F; Imren S; Morris SM; Pakiam F; Olson JM; Loken MR; Brodersen L; Riddell SR; Tarlock K; Bernstein ID; Loeb KR; Meshinchi S
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36136600
[TBL] [Abstract][Full Text] [Related]
58. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
[TBL] [Abstract][Full Text] [Related]
59. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
60. [Clinical features and prognosis of pediatric acute megakaryocytic leukemia].
Luo TM; Yu J; An XZ
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Jun; 23(6):613-620. PubMed ID: 34130784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
